

# Hai-Liang Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633139/publications.pdf>

Version: 2024-02-01

54  
papers

1,381  
citations

394421

19  
h-index

361022

35  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. <i>Annals of Medicine</i> , 2022, 54, 211-226.	3.8	10
2	Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study. <i>Bioengineered</i> , 2022, 13, 14000-14012.	3.2	6
3	Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3898-3911.	3.6	10
4	Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	3.6	19
5	Camrelizumab plus Famininib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study. <i>Clinical Cancer Research</i> , 2021, 27, 5838-5846.	7.0	14
6	Clear Cell Papillary Renal Cell Carcinoma Shares Distinct Molecular Characteristics and may be Significantly Associated With Higher Risk of Developing Second Primary Malignancy. <i>Pathology and Oncology Research</i> , 2021, 27, 1609809.	1.9	2
7	Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. <i>International Journal of Biological Sciences</i> , 2021, 17, 2205-2222.	6.4	36
8	Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. <i>Frontiers in Oncology</i> , 2021, 11, 762547.	2.8	1
9	Inactivation of the AMPK-GATA3-ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth. <i>Cancer Research</i> , 2020, 80, 319-333.	0.9	90
10	Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 1552-1562.	2.6	18
11	Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3124-3134.	2.6	12
12	&lt;p&gt;High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10453-10464.	2.0	11
13	Identification, Validation, and Functional Annotations of Genome-Wide Profile Variation between Melanocytic Nevus and Malignant Melanoma. <i>BioMed Research International</i> , 2020, 2020, 1-19.	1.9	7
14	Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma. <i>Journal of Cancer</i> , 2020, 11, 6101-6113.	2.5	6
15	Large-scale transcriptome profiles reveal robust signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9012-9027.	3.6	28
16	Development and validation of a robust multigene signature as an aid to predict early relapse in stage III clear cell and papillary renal cell cancer. <i>Journal of Cancer</i> , 2020, 11, 997-1007.	2.5	9
17	Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 866-883.	3.1	17
18	Fatty acid-binding protein 5 predicts poor prognosis in patients with uveal melanoma. <i>Oncology Letters</i> , 2020, 19, 1771-1780.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. <i>Journal of Cancer</i> , 2019, 10, 4333-4340.	2.5	23
20	Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 363.	4.4	46
21	Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma. <i>Frontiers in Genetics</i> , 2019, 10, 821.	2.3	28
22	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients. <i>Journal of Cancer</i> , 2019, 10, 4522-4531.	2.5	29
23	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 879.	2.8	6
24	Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 75-82.	1.0	3
25	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	1.6	1
26	The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma. <i>Medical Science Monitor</i> , 2019, 25, 9458-9470.	1.1	8
27	C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. <i>Medical Science Monitor</i> , 2019, 25, 8984-8994.	1.1	1
28	Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma. <i>Aging</i> , 2019, 11, 6503-6521.	3.1	13
29	Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. <i>Aging</i> , 2019, 11, 6999-7020.	3.1	163
30	Screening, identification and validation of CCND1 and PECAM1/CD31 for predicting prognosis in renal cell carcinoma patients. <i>Aging</i> , 2019, 11, 12057-12079.	3.1	26
31	Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: Real-world data from a single Chinese center.. <i>Journal of Clinical Oncology</i> , 2019, 37, 570-570.	1.6	0
32	An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 634.	2.8	24
33	Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. <i>BMC Cancer</i> , 2017, 17, 16.	2.6	25
34	Nephrometry score-guided off-clamp laparoscopic partial nephrectomy: patient selection and short-time functional results. <i>World Journal of Surgical Oncology</i> , 2016, 14, 163.	1.9	10
35	Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. <i>Oncology Letters</i> , 2016, 11, 879-883.	1.8	24
36	Small-Conductance Ca <sup>2+</sup> -Activated Potassium Channels Negatively Regulate Aldosterone Secretion in Human Adrenocortical Cells. <i>Hypertension</i> , 2016, 68, 785-795.	2.7	24

#	ARTICLE	IF	CITATIONS
37	Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population. <i>Scientific Reports</i> , 2016, 6, 36264.	3.3	12
38	MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai. <i>Scientific Reports</i> , 2016, 6, 36290.	3.3	7
39	Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 373-378.	2.2	23
40	Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. <i>Oncotarget</i> , 2016, 7, 68943-68953.	1.8	6
41	Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 713.	2.0	3
42	MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0124410.	2.5	58
43	Impact of preoperative 5 $\alpha$ -reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. <i>BMC Urology</i> , 2015, 15, 47.	1.4	33
44	Evaluation of fine particles in surgical smoke from an urologist's operating room by time and by distance. <i>International Urology and Nephrology</i> , 2015, 47, 1671-1678.	1.4	33
45	Pathological Features of Localized Prostate Cancer in China: A Contemporary Analysis of Radical Prostatectomy Specimens. <i>PLoS ONE</i> , 2015, 10, e0121076.	2.5	18
46	Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer. <i>Oncotarget</i> , 2015, 6, 18460-18468.	1.8	20
47	Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. <i>Oncotarget</i> , 2015, 6, 36870-36883.	1.8	14
48	Association of glutathione S-transferase T1 and M1 polymorphisms with prostate cancer susceptibility in populations of Asian descent: a meta-analysis. <i>Oncotarget</i> , 2015, 6, 35843-35850.	1.8	7
49	Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 925.	2.0	32
50	Long noncoding RNA expression signatures of bladder cancer revealed by microarray. <i>Oncology Letters</i> , 2014, 7, 1197-1202.	1.8	41
51	Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 82-85.	1.9	7
52	c-KIT: Potential Predictive Factor for the Efficacy of Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Feature. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 134-140.	1.9	13
53	Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. <i>International Journal of Urology</i> , 2011, 18, 422-430.	1.0	13
54	Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. <i>Prostate</i> , 2011, 71, 326-331.	2.3	287